Connect Biopharma’s pursuit of Bristol Myers Squibb and Pfizer has hit trouble, with a midphase failure in ulcerative colitis sending the biotech’s stock down over 30% to $1.30 apiece in premarket ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results